Learn how molecular glue small molecules rewire protein–protein interactions, enable targeted protein degradation, and unlock “undruggable” targets in oncology, neurology, and immunology. Explore their mechanism, history from thalidomide to rational design, and role in AI-driven drug discovery.
Learn how PROTAC small molecules are redefining cancer therapy by harnessing targeted protein degradation to eliminate “undruggable” oncogenic drivers, overcome resistance, and expand the frontier of small molecule oncology.